Opinion on Company Issues in North America

Published within

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Alteon: ALT-711 could generate $1.3 billion by 2010

Although the results of a US study show ISH continues to be under treated, this represents an opportunity for Alteon, which is developing ALT-711 specifically for ISH. Providing awareness of ISH is increased, Datamonitor forecasts that ALT-711 could generate sales of $1.3 billion by 2010, just three years after launch.<BR />

Published By Datamonitor
28 Mar 2003
CommentWire
CommentWire

Starbucks: from strength to strength

Strong 2002 results and high hopes for 2003 were key messages to stockholders at Starbucks' recent AGM. Through full use of modern technology, innovative rewards programs and old-fashioned physical expansion, Starbucks looks set for further growth despite current economic and political instabilities.<BR />

Published By Datamonitor
28 Mar 2003
CommentWire
CommentWire

Ingenium: tackling pain with Elan

Elan has formed a collaborative drug development agreement with Ingenium, a functional genomics company. The agreement enhances Elan's drug development capabilities and helps it build a strong CNS pipeline, a key part of its recovery plan.<BR />

Published By Datamonitor
27 Mar 2003
CommentWire
CommentWire

Sun: making friends and influencing people

Project Orion, which Sun has implemented to unify its product release cycles, has been designed partly to appeal to independent software vendors. Sun wants to ensure that many companies are working with the Sun ONE applications and web services stack, offering specialist services that Sun cannot cover.

Published By Datamonitor
26 Mar 2003
CommentWire
CommentWire

Anti-spam software: pure-play vendors at a disadvantage

The three major anti-virus software vendors are all building on their anti-spam offerings. Symantec, Trend Micro and Network Associates are all fighting for a share of the growing market. With these established players making moves, pure-play spam filter vendors will have a hard time gaining much market share without being acquired.

Published By Datamonitor
26 Mar 2003
CommentWire
CommentWire

EDS: new top execs get warm welcome

While Michael Jordan begins his career at EDS in the top role, the freshly reinstated position of president and COO is to be taken by a former occupant, Jeffrey Heller. Speculation is rife over whether EDS is likely to be acquired, as its low share price may make it tempting to some of the industry's larger players.

Published By Datamonitor
24 Mar 2003
CommentWire
CommentWire

Goodyear: fighting to stay on the road

Goodyear has elected to sell off its chemicals business in order to increase its financial security. Despite talks and a sell-off plan, Goodyear's shares are at an all time low and the woes of the company are far from over.<BR />

Published By Datamonitor
24 Mar 2003
CommentWire
CommentWire

Cisco Systems: heading for SOHO

Cisco is to pay $500 million to buy The Linksys Group, which specializes in the small and home office networks market. As corporate spending continues to be restrained by the economic climate, the market for home networking is still growing, driven by the increased availability of inexpensive broadband access.

Published By Datamonitor
24 Mar 2003
CommentWire
CommentWire

Pfizer: sale of a potential blockbuster

Pfizer's decision to keep Detrol and divest darifenacin to Novartis for $225 million is based purely on forecast projections. Detrol also has short-term blockbuster potential, while darifenacin may not offer significant advantages over Detrol or Johnson & Johnson's Ditropan, limiting its market penetration.

Published By Datamonitor
20 Mar 2003
CommentWire
CommentWire

Barr: generic Adderall gets attention

Shire's Adderall made over $400 million in 2002, and is one of the leading therapies used to treat children with attention deficit/hyperactive disorder (ADHD). Barr is unlikely to capture much of Shire's market share because the approval is for the older twice-daily version - less popular than Shire's convenient once-daily Adderall XR.

Published By Datamonitor
20 Mar 2003

« | ... | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | ... | » »|

No help is available.